JP2024016042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016042A5 JP2024016042A5 JP2023177190A JP2023177190A JP2024016042A5 JP 2024016042 A5 JP2024016042 A5 JP 2024016042A5 JP 2023177190 A JP2023177190 A JP 2023177190A JP 2023177190 A JP2023177190 A JP 2023177190A JP 2024016042 A5 JP2024016042 A5 JP 2024016042A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cdr
- seq
- administered
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025089576A JP2025143252A (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598402P | 2017-12-13 | 2017-12-13 | |
| US62/598,402 | 2017-12-13 | ||
| US201862701354P | 2018-07-20 | 2018-07-20 | |
| US62/701,354 | 2018-07-20 | ||
| PCT/US2018/065568 WO2019118791A1 (en) | 2017-12-13 | 2018-12-13 | Fcrn antibodies and methods of use thereof |
| JP2020532551A JP7420720B2 (ja) | 2017-12-13 | 2018-12-13 | ＦｃＲｎ抗体およびその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532551A Division JP7420720B2 (ja) | 2017-12-13 | 2018-12-13 | ＦｃＲｎ抗体およびその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025089576A Division JP2025143252A (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024016042A JP2024016042A (ja) | 2024-02-06 |
| JP2024016042A5 true JP2024016042A5 (enExample) | 2024-07-04 |
| JP7690538B2 JP7690538B2 (ja) | 2025-06-10 |
Family
ID=65041911
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532551A Active JP7420720B2 (ja) | 2017-12-13 | 2018-12-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2023177190A Active JP7690538B2 (ja) | 2017-12-13 | 2023-10-13 | ＦｃＲｎ抗体およびその使用方法 |
| JP2025089576A Pending JP2025143252A (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532551A Active JP7420720B2 (ja) | 2017-12-13 | 2018-12-13 | ＦｃＲｎ抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025089576A Pending JP2025143252A (ja) | 2017-12-13 | 2025-05-29 | ＦｃＲｎ抗体およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11773168B2 (enExample) |
| EP (1) | EP3723802A1 (enExample) |
| JP (3) | JP7420720B2 (enExample) |
| CN (1) | CN111712259A (enExample) |
| AU (1) | AU2018386193B2 (enExample) |
| BR (1) | BR112020011310A2 (enExample) |
| CA (1) | CA3085751A1 (enExample) |
| IL (1) | IL275070A (enExample) |
| SG (1) | SG11202005021PA (enExample) |
| WO (1) | WO2019118791A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118638229A (zh) | 2015-01-30 | 2024-09-13 | 动量制药公司 | Fcrn抗体及其使用方法 |
| JP7422659B2 (ja) | 2017-12-08 | 2024-01-26 | アルジェニクス ビーブイ | 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用 |
| JP7420720B2 (ja) | 2017-12-13 | 2024-01-23 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| MX2020013195A (es) | 2018-06-08 | 2021-02-26 | Argenx Bvba | Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria. |
| CA3148826A1 (en) * | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| FI4087875T3 (fi) | 2020-01-08 | 2024-10-25 | argenx BV | Vastasyntyneen ihmisen Fc-reseptorin (FcRn) antagonisteja pemfigus-häiriöiden hoitoon |
| US20230220069A1 (en) * | 2020-06-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| EP4240417A4 (en) * | 2020-11-06 | 2024-10-02 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
| CN116234827A (zh) * | 2021-09-03 | 2023-06-06 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| CN114129730A (zh) * | 2021-09-16 | 2022-03-04 | 宁夏大学 | FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用 |
| WO2023135321A1 (en) * | 2022-01-17 | 2023-07-20 | argenx BV | Methods for treating patients with an autoantibody-mediated disease |
| WO2023242372A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Fcrn/hsa binding molecules and methods of use |
| TW202517676A (zh) | 2023-07-05 | 2025-05-01 | 比利時商艾伯霖克斯公司 | 用於治療ＩｇＧ相關疾病及病症之改良ＦｃＲｎ拮抗劑 |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025186787A1 (en) * | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04007924A (es) | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| EP1660128A4 (en) | 2003-08-08 | 2009-01-21 | Univ New York State Res Found | ANTI-CORR ANTI-BODIES FOR THE TREATMENT OF AUTO / ALLO-IMMUNE DISORDERS |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| KR100996801B1 (ko) | 2005-03-08 | 2010-11-25 | 파마시아 앤드 업존 캄파니 엘엘씨 | 항-ＭＡｄＣＡＭ 항체 조성물 |
| WO2007087289A2 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| JP2009529339A (ja) | 2006-03-13 | 2009-08-20 | アブリンクス エン．ヴェー． | Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド |
| BRPI0910622A2 (pt) | 2008-04-25 | 2020-03-10 | Dyax Corp. | ANTICORPOS CONTRA FcRn E USOS DOS MESMOS |
| CA2766065C (en) | 2009-06-30 | 2020-07-21 | Research Development Foundation | Immunoglobulin fc polypeptides |
| TWI560200B (en) * | 2011-05-25 | 2016-12-01 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders |
| ES2748583T3 (es) | 2011-06-02 | 2020-03-17 | Dyax Corp | Proteínas de unión al receptor Fc |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| EP2934587A4 (en) | 2012-12-18 | 2016-08-03 | Merck Sharp & Dohme | Liquid formulations for an anti-TNF-alpha-antibody |
| ES2802274T3 (es) | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| JP6449441B2 (ja) | 2014-04-30 | 2019-01-09 | ハノル バイオファーマ カンパニーリミテッドＨａｎａｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． | ＦｃＲｎ特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物 |
| CN118638229A (zh) | 2015-01-30 | 2024-09-13 | 动量制药公司 | Fcrn抗体及其使用方法 |
| ES2956662T3 (es) * | 2015-05-12 | 2023-12-26 | Syntimmune Inc | Anticuerpos anti-FcRn humanizados con afinidad madurada |
| WO2018023136A1 (en) | 2016-07-29 | 2018-02-01 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| JP6913527B2 (ja) | 2017-06-22 | 2021-08-04 | 株式会社小松製作所 | 油圧ポンプおよびモータ |
| JP7422659B2 (ja) | 2017-12-08 | 2024-01-26 | アルジェニクス ビーブイ | 全身型重症筋無力症治療のためのＦｃＲｎアンタゴニストの使用 |
| JP7420720B2 (ja) | 2017-12-13 | 2024-01-23 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| US20210139582A1 (en) | 2018-02-13 | 2021-05-13 | The Brigham And Women's Hospital, Inc. | Therapeutic fcrn-based bispecific monoclonal antibodies |
| MX2021000790A (es) | 2018-07-20 | 2021-07-21 | Momenta Pharmaceuticals Inc | Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas. |
| IL280278B2 (en) | 2018-07-20 | 2025-10-01 | Momenta Pharmaceuticals Inc | Fcrn antibody preparations |
| EP3866933A1 (en) | 2018-10-16 | 2021-08-25 | UCB Biopharma SRL | Method for the treatment of myasthenia gravis |
| CA3148826A1 (en) | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| EP4240417A4 (en) | 2020-11-06 | 2024-10-02 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
-
2018
- 2018-12-13 JP JP2020532551A patent/JP7420720B2/ja active Active
- 2018-12-13 AU AU2018386193A patent/AU2018386193B2/en active Active
- 2018-12-13 CN CN201880089334.7A patent/CN111712259A/zh active Pending
- 2018-12-13 SG SG11202005021PA patent/SG11202005021PA/en unknown
- 2018-12-13 EP EP18836751.0A patent/EP3723802A1/en active Pending
- 2018-12-13 US US16/771,147 patent/US11773168B2/en active Active
- 2018-12-13 BR BR112020011310-7A patent/BR112020011310A2/pt unknown
- 2018-12-13 WO PCT/US2018/065568 patent/WO2019118791A1/en not_active Ceased
- 2018-12-13 CA CA3085751A patent/CA3085751A1/en active Pending
-
2020
- 2020-06-02 IL IL275070A patent/IL275070A/en unknown
-
2023
- 2023-08-18 US US18/452,346 patent/US20240158509A1/en active Pending
- 2023-10-13 JP JP2023177190A patent/JP7690538B2/ja active Active
-
2025
- 2025-05-29 JP JP2025089576A patent/JP2025143252A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016042A5 (enExample) | ||
| JP2021506786A5 (enExample) | ||
| JP2019526540A5 (enExample) | ||
| JP7442575B2 (ja) | Ｆｃｒｎ抗体及びその使用方法 | |
| AU2008207338B2 (en) | Treatment of chronic joint inflammation using an antibody against the CD3 antigen complex | |
| US20220144946A1 (en) | Fcrn antibodies and methods of use thereof | |
| CN114630678A (zh) | FcRn抗体及其使用方法 | |
| BRPI0711908B1 (pt) | Anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo | |
| JPWO2019231983A5 (enExample) | ||
| EA050428B1 (ru) | АНТИТЕЛА ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| HK40072884A (en) | Fcrn antibodies and methods of use thereof | |
| JPH04120025A (ja) | インターロイキン―６の作用増強剤 | |
| JPH07126299A (ja) | ヒト型モノクローナル抗体 |